Effect of antimicrobial preservatives on partial protein unfolding and aggregation

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 365-376

  Hutchings, Regina L ^a   Singh, Surinder M ^a   Cabello Villegas, Javier ^a   Mallela, Krishna M G ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antimicrobial preservatives; Benzyl alcohol; Chlorobutanol; Cytochrome c; M cresol; Phenol; Phenoxyethanol; Protein aggregation; Protein formulations; Protein structure; Proteins; Stability

Indexed keywords

2 PHENOXYETHANOL; BENZYL ALCOHOL; CHLORBUTOL; CYTOCHROME C; META CRESOL; PHENOL; PRESERVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; PROTEIN AGGREGATION; PROTEIN UNFOLDING;

EID: 84872495852     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23362     Document Type: Article

References (53)

1. Trissel LA. 2010. Handbook on injectable drugs. 16th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.
2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: An update. Pharm Res 27:544-575.
3. Meyer BK, Ni A, Hu B, Shi L. 2007. Antimicrobial preservative use in parenteral products: Past and present. J Pharm Sci 96:3155-3167.
4. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations-A close look at protein aggregation, deamidation and oxidation. Crit Rev Ther Drug Carrier Syst 10:307-377.
5. Akers MJ, Vasudevan V, Stickelmeyer M. 2002. Formulation development of protein dosage forms. In Development and manufacture of protein pharmaceuticals; Nail SL, Akers MJ, Eds. New York City, New York: Kluwer Academic/Plenum Publishers, pp 47-127.
6. Geier DA, Sykes LK, Geier MR. 2007. A review of thimerosal (Merthiolate) and its ethylmercury breakdown product: Specific historical considerations regarding safety and effectiveness. J Toxicol Environ Health B Crti Rev 10:575-596.
7. Batorova A, Martinowitz U. 2002. Continuous infusion of coagulation factors. Haemophilia 8:170-177.
8. Jorgensen JT, Mortensen HB, Jorgensen JO. 1991. Patient acceptance of Nordiject: A new drug delivery system for growth hormone. DICP: Ann Pharmacother 25:585-588.
9. Maa YF, Hsu CC. 1996. Aggregation of recombinant human growth hormone induced by phenolic compounds. Int J Pharm 140:155-168.
10. Tobler SA, Holmes BW, Cromwell MEM, Fernandez EJ. 2004. Benzyl alcohol-induced destabilization of interferon-γ. J Pharm Sci 39:7161-5061.
11. Roy S, Katayama D, Dong A, Kerwin BA, Randolph TW, carpenter JF. 2006. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry 45:3898-3911.
12. Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF. 2006. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95:1480-1497.
13. Katakam M, Banga AK. 1997. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. Pharm Dev Technol 2:143-149.
14. Remmele Jr. RL, Nightlinger NS, Srinivasan S, Gombotz WR. 1998. Interleukin-1 receptor (IL-1RA) liquid formulation development using differential scanning calorimetry. Pharm Res 15:200-208.
15. Gupta S, Kaisheva E. 2003. Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques. AAPS Pharm Sci 5:1-9.
16. Ratner RE, Phillips TM, Steiner M. 1990. Persistent cutaneous insulin allergy resulting from high molecular weight insulin aggregates. Diabetes 39:728-733.
17. Thornton CA, Ballow M. 1993. Safety of intravenous immunoglobulin. Arch Neurol 50:135-136.
18. Wright PE, Dyson HJ. 2009. Linking folding and binding. Curr Opin Struct Biol 19:31-38.
19. Hassoun H, Vassiliadis JN, Murray J, Njolstad PR, Rogus JJ, Ballas SK, Schaffer F, Jarolim P, Brabec V, Palek J. 1997. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 90:398-406.
20. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formingli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507-511.
21. Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong H-Q, Mathis BJ, Rodríguez-Pérez J-C, Allen PG, Beggs AH, Pollak MR. 2000. Mutations in ACTN4, encoding -actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251-256.
22. Cheung MS, Chavez LL, Onuchic JN. 2004. The energy landscape for protein folding and possible connections to function. Polymer 45:547-555.
23. Rosenberg AS. 2006. Effects of protein aggregation: An immunologic perspective. AAPS J 8:E501-E507.
24. Robertson SP, Twigg SRF, Sutherland-Smith AJ, Biancalana V, Gorlin RJ, Horn D, Kenwrick SJ, Kim CA, Morava E, Newbury-Ecob R, Ørstavik KH, Quarrell OWJ, Schwartz CE, Shears DJ, Suri M, Kendrick-Jones J, Bacino C, Becker K, Clayton-Smith J, Giovannucci-Uzielli M, Goh D, Grange D, Krajewska-Welasek M, Lacombe D, Morris C, Odent S, Savarirayan R, Stratton R, Superti-Furga A, Verloes A, Vigneron J, Wilcox W, Winter R, Young K, Wilkie AOM. 2003. Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. Nat Genet 33:487-491.
25. Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98:3247-3264.
26. Sauerborn M, Brinks V, Jiskoot W, Schellekens H. 2010. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31:53-59.
27. Vazquez-Rey M, Lang DA. 2011. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 108:1494-1508.
28. Bai Y, Sosnick TR, Mayne L, Englander SW. 1995. Protein folding intermediates: Native-state hydrogen exchange. Science 269:192-197.
29. Maity H, Maity M, Krishna MMG, Mayne L, Englander SW. 2005. Protein folding: The stepwise assembly of foldon units. Proc Natl Acad Sci USA 102:4741-4746.
30. Krishna MMG, Maity H, Rumbley JN, Lin Y, Englander SW. 2006. Order of steps in the cytochrome c folding pathway: Evidence for a sequential stabilization mechanism. J Mol Biol 359:1411-1420.
31. Englander SW, Mayne L, Krishna MMG. 2007. Protein folding and misfolding: Mechanism and Principles. Q Rev Biophysics 40:287-326.
32. Russell BS, Melenkivitz R, Bren KL. 2000. NMR investigation of ferricytochrome c unfolding: Detection of an equilibrium unfolding intermediate and residual structure in the denatured state. Proc Natl Acad Sci USA 97:8312-8317.
33. Maity H, Rumbley JN, Englander SW. 2006. Functional role of a protein foldon-An Ω-loop foldon controls the alkaline transition in ferricytochrome c. Proteins 63:349-355.
34. Bandi S, Bowler BE. 2008. Probing the bottom of a folding funnel using conformationally gated electron transfer reactions. J Am Chem Soc 130:7540-7541.
35. Zang C, Stevens JA, Link JJ, Guo L, Wang L, Zhong D. 2009. Ultrafast proteinquake dynamics in cytochrome c. J Am Chem Soc 131:2846-2852.
36. Singh SM, Cabello-Villegas J, Hutchings RL, Mallela KMG. 2010. Role of partial protein unfolding in alcohol-induced protein aggregation. Proteins 78:2625-2637.
37. Hirota S, Hattori Y, Nagao S, Taketa M, Komori H, Kamikubo H, Wang Z, Takahashi I, Negi S, Sugiura Y, Kataoka M, Higuchi Y. 2010. Cytochrome c polymerization by successive domain swapping at the C-terminal helix. Proc Natl Acad Sci USA 107:12854-12859.
38. Kraulis PJ. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:945-949.
39. Margoliash E, Frohwirt N. 1959. Spectrum of horse-heart cytochrome c. Biochem J 71:570-572.
40. Bowler BE, May K, Zaragoza T, York P, Dong A, Caughey WS. 1993. Destabilizing effects of replacing a surface lysine of cytochrome c with aromatic amino acids: Implications for the denatured state. Biochemistry 32:183-190.
41. Creutz C, Sutin N. 1973. Reduction of ferricytochrome c by dithionite ion: Electron transfer by parallel adjacent and remote pathways. Proc Natl Acad Sci USA 6:1701-1703.
42. Sutton SVW, Porter D. 2002. Development of the antimicrobial effectiveness test as USP chapter <51>. PDA J Pharm Sci Techol 65:113-003.
43. Pace CN. 1986. Determination and analysis of urea and guanidine hydrochloride denaturation curves. Methods Enzymol 131:266-280.
44. Santoro MM, Bolen DW. 1988. Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl alpha-chymotrypsin using different denaturants. Biochemistry 27:8063-8068.
45. Santoro MM, Bolen DW. 1992. A test of the linear extrapolation of unfolding free energy changes over an extended denaturant concentration range. Biochemistry 31:4901-4907.
46. Feng Y, Roder H, Englander SW, Wand AJ, Stefano DLD. 1989. Proton resonance assignments of horse ferricytochrome c. Biochemistry 28:195-203.
47. Zhang Y, Roy S, Jones LS, Krishnan S, Kerwin BA, Chang BS, Manning MC, Randolph TW, Carpenter JF. 2004. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1-receptor antagonist in aqueous solution. J Pharm Sci 93:3076-3089.
48. Singh SM, Hutchings RL, Mallela KMG. 2011. Mechanisms of m-cresol-induced protein aggregation studied using a model protein cytochrome c. J Pharm Sci 100:1679-1689.
49. Krishna MMG, Hoang L, Lin Y, Englander SW. 2004. Hydrogen exchange methods to study protein folding. Methods 34:51-64.
50. Xu Y, Mayne L, Englander SW 1998. Evidence for an unfolding and refolding pathway in cytochrome c. Nature Struct Biol 5:774-778.
51. Banci L, Bertini I, Huber JG, Spyroulias GA, Turano P. 1999. Solution structure of reduced horse heart cytochrome c. J Biol Inorg Chem 4:21-31.
52. Yang Y, Petkova A, Huang K, Xu B, Hua Q-X, Ye I-J, Chu Y-C, Hu S-Q, Phillips NB, Whittaker J, Ismail-Beigi F, Mackin RB, Katsoyannis PG, Tycko R, Weiss MA. 2010. An Achilles' heel in an amyloidogenic protein and its repair. Insulin fibrillation and therapeutic design. J Biol Chem 285:10806-10821.
53. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. 2009. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 106:11937-11942.